Algernon NeuroScience
  • HOME
  • ABOUT
    • Overview
    • Structure & Valuation
    • Management Team
    • Board of Directors
    • Medical & Scientific Advisors
  • PIPELINE
    • Overview
    • DMT Program For Stroke
    • DMT Program For Traumatic Brain Injury (TBI)
  • INVEST
  • NEWS & MEDIA
    • News Releases
    • Presentations
    • Events
    • Videos & Articles
  • COMPANY
    • Company
    • Our Team
    • Presentations
    • Contacts
    • FAQ
  • CONTACT
Select Page
Mackie Research sets a speculative target of $.80 per share for Algernon Pharmaceuticals

Mackie Research sets a speculative target of $.80 per share for Algernon Pharmaceuticals

Aug 23, 2020

MACKIE RESEARCH REPORT SUMMARY   ALGERNON PHARMACEUTICALS INC. – SPECULATIVE BUY We are initiating coverage of Algernon Pharmaceuticals (AGN-CSE) with a SPECULATIVE BUY recommendation and a target price of $0.80/share. Banking on a Unique Drug Repurposing...

Recent Posts

  • The Dales Report – Why Psychedelic Treatments Will Benefit Investors and Healthcare
  • Radius Research Interview – Algernon NeuroScience Initiates TBI Research Program with DMT
  • Proactive Investors CEO Interview – Algernon NeuroScience completes first dosing in Phase 1 clinical study of DMT
  • SR Times – “Drug Could Possibly Both Reduce Acute Damage of the Stroke” – How DMT Could be the Future of Stroke Treatment
  • Radius Research Interview – Algernon Pharmaceuticals (AGN) CEO Christopher J. Moreau – Ifendprodil Program Update Targeting Chronic Cough

Recent Comments

No comments to show.

Subscribe to Algernon NeuroScience

Sign up today and receive company media releases and updates straight to your inbox.

Success!

Subscribe

  • HOME
  • INVEST
  • ABOUT
  • PIPELINE
  • NEWS & MEDIA
  • COMPANY
  • CONTACT

© Algernon NeuroScience – All Rights Reserved 2023      Privacy Policy